ロード中...
Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer
PURPOSE: Samarium-153 ((153)Sm) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and a favorable toxicity profile. We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-re...
保存先:
| 出版年: | J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4371137/ https://ncbi.nlm.nih.gov/pubmed/19414670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.5393 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|